
HHS says it will begin reforms of organ donation system after federal investigation finds ‘horrifying' problems
A House subcommittee is holding a hearing Tuesday on organ donation safety lapses and how procurement and transplant organizations intend to improve the system, to regain the trust of donors and their families. That trust is essential because the US organ donation system relies on people to volunteer to donate, often when they get a driver's license.
As of 2022, about 170 million people in the US have signed up to donate their organs when they die, but there is always more demand for organs than what is available. Last year, there were more than 48,000 transplants in the US, but more than 103,000 people were on waiting lists. About 13 people in the United States die every day waiting for a transplant, according to the federal Health Resources and Services Administration.
HHS says the reform initiative was launched after an investigation by the Health Resources and Services Administration found problems with dozens of cases involving incomplete donations – when an organization started the process to take someone's organs but, for some reason, the donation never happened.
According to a report on the federal investigation, as well as a memo prepared ahead of the House subcommittee hearing, the cases were managed by Kentucky Organ Donor Affiliates, a procurement organization that handles donations in Kentucky and parts of Ohio and West Virginia, which has merged with another group and is now called Network for Hope.
Of the 351 cases in the investigation, more than 100 had 'concerning features, including 73 patients with neurological signs incompatible with organ donation,' HHS said in a news release Monday. At least 28 cases involved patients who may not have been deceased at the time the organ procurement process began, raising 'serious ethical and legal questions.'
'Our findings show that hospitals allowed the organ procurement process to begin when patients showed signs of life, and this is horrifying,' HHS Secretary Robert F. Kennedy Jr. said in the release. 'The organ procurement organizations that coordinate access to transplants will be held accountable. The entire system must be fixed to ensure that every potential donor's life is treated with the sanctity it deserves.'
Network for Hope has not responded to CNN's request for comment, but it says on its website that it is 'fully committed to transparency' and is in full compliance with all requirements of the Centers for Medicare & Medicaid Services, which regulates organ donation organizations. 'Our goal has always been and will remain to meet the highest ethical and medical standards in donation and transplantation.'
The investigation found patterns such as failures to follow professional best practices, to respect family wishes, to collaborate with a patient's primary medical team, and to recognize neurological function, suggesting 'organizational dysfunction and poor quality and safety assurance culture' in the Kentucky-area organization, according to a report from the Health Resources and Services Administration.
The investigation also found that the Kentucky-area organization and the Organ Procurement and Transplantation Network, which oversees the local groups, failed to 'adequately recognize and respond to poor patient care and quality practices,' the report says.
The organ procurement organization in Kentucky is one of 55 in the US, and since the federal review, the Health Resources and Services Administration said, it has received reports of 'similar patterns' of high-risk procurement practices at other organizations.
The agency is mandating system-level changes to safeguard potential organ donors across the US and said the Kentucky-area organization needed to conduct a 'full root cause analysis of its failures to follow internal protocols.' It also said the organization must adopt a formal procedure to halt a donation process if there are safety concerns.
Network for Hope says on its website: 'We are equally committed to addressing the recent guidance from the HRSA and we are already evaluating whether any updates to our current practices are needed.'
The federal investigation was launched after one case in Kentucky came to light during a congressional hearing in September.
In 2021, 33-year-old TJ Hoover was hospitalized after a drug overdose. He woke up in the operating room to find people shaving his chest, bathing his body in surgical solution and talking about harvesting his organs. Earlier that day, a doctor had declared him brain-dead, according to his medical records, even though he seemed to be reacting to stimuli, making eye contact and shaking his head.
Former staffers of the organ procurement organization who were involved in Hoover's case raised concerns that he wasn't brain-dead and should not have been on the operating table. The concerns were ignored, according to the federal investigation.
Staff told CNN that the procedure to take Hoover's organs stopped after a surgeon saw his reaction to stimuli. The Kentucky procurement organization told CNN last fall that it had reviewed the case and 'remains confident that accepted practices and approved protocols were followed.'
Hoover now lives with his sister in Richmond, Kentucky, and is undergoing extensive physical therapy and treatment, much of which is shared on TikTok in an effort to inspire others.
Congress has been investigating the nation's organ donation system for years. Tuesday's hearing is intended to determine what lessons could be learned from the investigation, what changes are necessary to make the system better and what challenges lie ahead.
One issue involves organs procured from patients who aren't brain-dead. Although most donations in the US come from people who are brain-dead, there are other circumstances in which a patient may become an organ donor. It's called donation after circulatory death, or DCD, and it has become much more common in recent years, although some experts question the ethics of the practice.
A donation after brain death is defined by the Organ Procurement and Transplantation Network as 'the organ recovery process that may occur following death by irreversible cessation of cerebral and brain stem function; characterized by absence of electrical activity in the brain, blood flow to the brain, and brain function as determined by clinical assessment of responses.'
DCD, by comparison, is when 'you've got somebody with essentially devastating illness or injury, and their family's decided to withdraw life support,' Dr. Robert Cannon, an associate professor of surgery and surgical director of the liver transplant program at the University of Alabama at Birmingham, told CNN last year after Hoover's case came to light.
Cannon was not involved in Hoover's case but was familiar with it because he testified about lapses in the organ procurement system at the House Energy and Commerce Oversight and Investigations Subcommittee hearing where the case came to light in September.
'Certainly, we have potential DCD donors with lots of reflexes,' Cannon said. 'But as long as the family knows this is what's happening with their loved one, this process is considered ethical and standard.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
A Closer Look at SunLink's (SSY) Special Dividend
SunLink Health Systems, Inc. (NYSEAMERICAN:SSY) is included among the 14 Stocks that Paid Special Dividends in 2025. A pharmacy technician in a laboratory preparing medication for retail distribution. SunLink Health Systems, Inc. (NYSEAMERICAN:SSY) delivers healthcare products and services in the southeastern US through its subsidiaries. Its operations are divided into two main segments: Healthcare Services and Pharmacy. On July 21, SunLink Health Systems, Inc. (NYSEAMERICAN:SSY) announced that its Board of Directors had approved a special cash dividend ahead of its planned merger with Regional Health Properties, as outlined in the amended merger agreement dated April 14, 2025. The special dividend, set at $0.10 per share, will be paid in cash to shareholders of record as of July 29, 2025. With 7,040,603 shares of SunLink's common stock outstanding as of June 20, 2025, the total estimated payout is approximately $704,600. The dividend is scheduled to be distributed on July 30, 2025. SunLink Health Systems, Inc. (NYSEAMERICAN:SSY) does not typically issue dividends, and this marked its first announcement of a special dividend. While we acknowledge the potential of SSY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
AstraZeneca's (AZN) Dividend: Resilient, Predictable, and Built on Innovation
AstraZeneca PLC (NASDAQ:AZN) is included among the Top 10 Safest Dividend Stocks in the UK. A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases. AstraZeneca PLC (NASDAQ:AZN) is well-positioned to handle upcoming patent expirations, thanks to a robust pipeline of drugs in development. By the close of the first quarter, the company had gained approval or label updates for roughly 13 treatments. Two of its most notable experimental drugs, AZD5004 and AZD6234, show potential in the weight management space. In total, the company is advancing nearly 200 research programs across its development pipeline. AstraZeneca PLC (NASDAQ:AZN) recently announced plans to invest $50 billion in the US by 2030. This initiative is expected to generate tens of thousands of direct and indirect jobs nationwide. A key part of the investment includes the development of a new multi-billion-dollar manufacturing site in the US, which will focus on producing drug substances for its weight management and metabolic treatments—such as oral GLP-1, baxdrostat, oral PCSK9, and combination small molecule therapies. This commitment comes on top of the $3.5 billion investment the company revealed in November 2024. AstraZeneca PLC (NASDAQ:AZN) is a solid dividend payer, as it has paid uninterrupted dividends to shareholders for the past 32 years. The company offers an interim dividend of $1.03 per share and has a dividend yield of 2.13%, as of July 25. While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.
Yahoo
4 hours ago
- Yahoo
Elevance Health, Inc. (ELV) Downgrades 2025 Earnings Amid Rising Medical Costs
We recently compiled a list of Elevance Health, Inc. stands third on our list among the most undervalued healthcare stocks. Elevance Health, Inc. (NYSE:ELV) is a major U.S. healthcare company, known for its insurance brands Anthem and WellPoint, and its growing Carelon health services arm. It serves around 45.6 million medical plan members and is recognized for integrating technology and value-based care to improve healthcare delivery. The company is facing increased healthcare utilization and rising medical costs, especially in the ACA and Medicaid segments. This has led to a downgrade in full-year 2025 earnings. A 'market-wide morbidity shift' is evident, with new ACA enrollees using emergency services at nearly double the rate of commercial members, and Medicaid patients showing higher acuity due to redeterminations. Amid these challenges, some investors see Elevance Health, Inc. (NYSE:ELV) as one of the most undervalued stocks in the healthcare sector, given its long-term positioning and strategic adjustments. The company expects a surge in elective procedures by Q4 2025 as members act ahead of expiring tax credits in 2026 that could raise their out-of-pocket costs. To address these pressures, the business is ramping up AI-driven tools for risk detection, care coordination, and operational efficiency. It's also expanding value-based care contracts, particularly in behavioral health and oncology, with over one-third of benefit expenses tied to risk-sharing models. The company is adjusting pricing strategies for ACA plans and advocating for Medicaid access amid potential regulatory changes. A healthcare professional discussing a treatment plan with a patient in an outpatient clinic. Though total membership fell by 212,000 in Q2 due to Medicaid attrition, the Medicare Advantage segment continues to grow. Elevance Health, Inc. (NYSE:ELV) is prioritizing long-term financial stability over aggressive member growth as it navigates rising costs, shifting regulations, and post-pandemic care patterns. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data